According to a proposed mechanism, HOXB13 binds to the promoter of the inflammatory cytokine interleukin 6 (IL-6) gene to induce its expression in breast cancer cells and exhibit anticancer drug resistance [13]. This evidence concerns the gene HOXB13 and breast carcinoma.